Literature DB >> 27483485

The increased demand for plasma-derived factor VIII in Italy.

Romano Arcieri1, Gabriele Calizzani2, Fabio Candura2, Pier Mannuccio Mannucci3.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27483485      PMCID： PMC5448839          DOI： 10.2450/2016.0156-16

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  3 in total

1.  Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy.

Authors:  Angiola Rocino; Antonio Coppola; Massimo Franchini; Giancarlo Castaman; Cristina Santoro; Ezio Zanon; Elena Santagostino; Massimo Morfini
Journal:  Blood Transfus       Date:  2014-10       Impact factor: 3.443

2.  Prophylaxis in haemophilia should be life-long.

Authors:  Mike Makris
Journal:  Blood Transfus       Date:  2012-02-13       Impact factor: 3.443

Review 3.  How we choose factor VIII to treat hemophilia.

Authors:  Pier Mannuccio Mannucci; Maria Elisa Mancuso; Elena Santagostino
Journal:  Blood       Date:  2012-03-12       Impact factor: 22.113
  3 in total
  3 in total

1.  Italian consumption of plasma-derived factor VIII after the SIPPET study.

Authors:  Giuseppe Traversa; Francesco Trotta
Journal:  Blood Transfus       Date:  2017-05       Impact factor: 3.443

2.  Recommendations for factor VIII product source to treat patients with haemophilia A.

Authors:  Romano Arcieri; Gabriele Calizzani; Fabio Candura; Pier Mannuccio Mannucci
Journal:  Blood Transfus       Date:  2017-03-02       Impact factor: 3.443

3.  The increased demand for plasma-derived factor VIII in Italy between 2011 and 2014 is attributable to treatment of adult patients rather than paediatric or previously unexposed patients with severe haemophilia A.

Authors:  Antonio Coppola; Elena Santagostino; Hamisa J Hassan; Angelo C Molinari; Rita C Santoro; Annarita Tagliaferri; Massimo Morfini; Giovanni Di Minno
Journal:  Blood Transfus       Date:  2017-03-02       Impact factor: 3.443
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.